Dr. Danielle A. Shafer, DO
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Midwestern University, Chicago College of Osteopathic Med (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 188
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Midwestern University, Chicago College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0102203473 -
Hematology (Internal Medicine) Physician
VA license 0102203473 -
Hematology & Oncology Physician
VA license 0102203473 -
Internal Medicine Physician
VA license 0102203473
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Inova Fairfax Hospital Falls Church, VA
- Inova Fair Oaks Hospital Fairfax, VA
- Inova Loudoun Hospital Leesburg, VA
Medical groups
- Inova Health Care Services (1,817 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 188
- Services billed
- 604
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 405 | 136 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 130 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 124 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 58 | 29 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 25 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Fairfax, VA | 33 |
| Eliquis (apixaban) Other prescribers in Fairfax, VA | 29 |
| Brukinsa (zanubrutinib) | 25 |
| Lenalidomide | 21 |
| Promacta (eltrombopag olamine) | 20 |
| Acyclovir Other prescribers in Fairfax, VA | 18 |
| Pantoprazole Sodium Other prescribers in Fairfax, VA | 18 |
| Allopurinol Other prescribers in Fairfax, VA | 16 |
| Ondansetron Hcl Other prescribers in Fairfax, VA | 16 |
| Sprycel (dasatinib) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $42,300 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG) plus Best Supportive Care (BSC) versus Placebo p…
Celgene Corporation - A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.